Paul Baas - Researcher Profile | RDL Research Database

Publications

2 shown

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst , Paul Baas , Dong‐Wan Kim +16 more

2015 The Lancet 6378 citations

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer , Karen L. Reckamp , Paul Baas +22 more

Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab tha...

2015 New England Journal of Medicine 8355 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 14,733
Institution: Amsterdam UMC Location University of Amsterdam

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-7018-9556

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.